Sylvester Stallone TRT: Public Transformation Timeline and Clinical Context

What Stallone Has Said Publicly About TRT

Stallone is one of the few Hollywood actors who has spoken about testosterone use on the record rather than through anonymous sourcing. In a 2008 interview with Time magazine, he stated directly: "Everyone over 40 years old would be wise to investigate [testosterone and HGH]. Growth hormone keeps you young. It produces collagen. It keeps your brain firing. I'm not doing anything that 10 million other people aren't doing." That statement does not constitute medical advice, but it does confirm first-person acknowledgment of hormone use.

His comments have been consistent across multiple interviews since then. Speaking to Muscle and Fitness in 2015, he described his training regimen for the later Rocky and Expendables films and credited disciplined diet, heavy resistance training, and hormone optimization for his physique at ages 60 through 65.

These are primary statements, not inference. Any claim beyond what Stallone has directly said is labeled as inference in this article.

The 2007 Australian Customs Incident

In February 2007, Australian customs officers at Sydney airport seized 48 vials of Jintropin, a brand of recombinant human growth hormone (somatropin), from Stallone's luggage. He was charged under the Customs Act and paid a fine of approximately AUD 10,500. Australian law requires a prescription for importation of growth hormone; Stallone did not have one at the time of entry.

This incident is a matter of public record documented by the Australian Department of Public Prosecutions. It is clinically relevant because HGH is often co-administered with testosterone in age-management protocols, a practice that raises distinct regulatory and safety considerations separate from TRT alone.

Inference: What His Physique Suggests

Stallone weighed approximately 175 lbs (79 kg) at 5'10" during the original Rocky (1976). By the time he filmed Rocky Balboa (2006) at age 60, published press materials reported a weight near 197 lbs with visibly lower body fat than his late-1980s Rambo films. Maintaining or increasing lean mass while reducing fat percentage across a 30-year span in a man older than 55 is atypical without pharmacological support. This is inference, not a confirmed statement from Stallone or his physicians.

Testosterone Decline in Men Over 50: The Clinical Picture

Testosterone does not drop off a cliff at 50. The decline is gradual, averaging 1 to 2 percent per year after age 30, according to data from the Baltimore Longitudinal Study of Aging [1]. By age 60, roughly 20 percent of men have total testosterone below 300 ng/dL, the threshold the Endocrine Society uses in its 2018 clinical practice guideline to define biochemical hypogonadism [2].

Symptoms That Prompt Testing

The Endocrine Society guideline recommends testing only in men with signs and symptoms consistent with hypogonadism: reduced libido, fatigue, loss of muscle mass, increased body fat, and mood changes [2]. A single morning serum total testosterone below 300 ng/dL on two separate occasions is the diagnostic threshold.

Free testosterone matters too. Sex hormone-binding globulin (SHBG) rises with age, binding more testosterone and leaving less biologically active. A man with total testosterone of 320 ng/dL but very high SHBG may have free testosterone below 65 pg/mL, the lower bound of the normal range cited by the American Association of Clinical Endocrinologists (AACE) [3].

What "Optimization" Means Clinically

Age-management clinics sometimes use the phrase "testosterone optimization" to describe treating men whose total testosterone falls in the low-normal range, say 300 to 450 ng/dL, to raise levels toward the upper half of the reference range. This practice is outside the scope of Endocrine Society guideline recommendations, which restrict TRT to men with confirmed hypogonadism [2]. The FDA-approved indication for testosterone products is hypogonadism, not age-related decline alone [4].

TRT Formulations: What the Options Actually Are

Stallone has not publicly specified which testosterone formulation he uses. The main options currently approved by the FDA include:

• Testosterone cypionate or enanthate injections: Typically 50 to 200 mg intramuscularly every 1 to 2 weeks, or smaller doses weekly to reduce peaks and troughs [4].
• Topical gels (AndroGel, Testim, Vogelxo): 1.62% or 2% testosterone applied daily; FDA-approved since 2000 [4].
• Testosterone pellets (Testopel): Implanted subcutaneously every 3 to 6 months, releasing 150 to 450 mg over the implant period [4].
• Nasal gel (Natesto): 11 mg applied intranasally three times daily; approved in 2014 [4].
• Oral testosterone undecanoate (Jatenzo, Kyzaiq): Taken twice daily with food; approved in 2019 [4].

Each formulation carries different pharmacokinetics, adherence profiles, and side-effect risks. Injections produce larger peaks and troughs; gels provide steadier levels but carry transfer risk to partners and children [4].

What Clinical Trials Show About TRT Benefits in Older Men

The Testosterone Trials (TTrials)

The TTrials were a set of seven coordinated, placebo-controlled trials funded by the National Institutes of Health and conducted at 12 U.S. Sites in 790 men aged 65 and older with low testosterone (below 275 ng/dL) [5]. Published in the New England Journal of Medicine in 2016, the Sexual Function Trial showed statistically significant improvements in sexual desire, erectile function, and activity at 12 months [5]. The Physical Function Trial found that testosterone increased 6-minute walk distance by a modest but statistically significant margin compared with placebo [5]. Body composition data from the same cohort showed a mean increase of approximately 1.6 kg in lean mass and a decrease of 1.6 kg in fat mass over 12 months [6].

These are real but modest gains. They do not describe the physique of a competitive bodybuilder.

The TRAVERSE Trial

TRAVERSE (N=5,246) was a cardiovascular safety trial published in the New England Journal of Medicine in 2023, comparing testosterone replacement to placebo in men aged 45 to 80 with hypogonadism and elevated cardiovascular risk [7]. At a median follow-up of 33 months, the primary cardiovascular endpoint (MACE: myocardial infarction, stroke, or cardiovascular death) occurred in 7.0% of the testosterone group vs. 7.3% in the placebo group, a non-inferiority result [7]. The trial did find a higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group, findings that inform current prescribing practice [7].

Bone Density

The Bone Trial within TTrials found that testosterone significantly increased volumetric bone density at the spine and hip compared with placebo at 12 months, with effects persisting at 24 months in an extension study published in JAMA Internal Medicine in 2017 [8].

Human Growth Hormone: Separate Drug, Separate Evidence

The 2007 customs incident involved HGH, not testosterone. These are distinct drugs with distinct regulatory status and evidence profiles.

Recombinant human growth hormone (somatropin) is FDA-approved for adult growth hormone deficiency, short bowel syndrome, and HIV-associated wasting [9]. It is not approved for age-related GH decline, athletic performance, or anti-aging. The FDA issued a specific advisory statement noting that "the prescribing of HGH for off-label purposes, such as anti-aging, is illegal" [9].

A 2007 meta-analysis published in the Annals of Internal Medicine (N=220 healthy older adults across 31 trials) found that GH administration increased lean body mass by 2.1 kg and decreased fat mass by 2.7 kg, but produced no improvement in functional outcomes and substantially increased rates of soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia [10]. The authors concluded that "the adverse effects of GH are frequent" and that the risk-benefit ratio does not support use in healthy aging adults [10].

GH and Cancer Risk

Elevated IGF-1, the primary mediator of GH effects, is associated with increased risk of colorectal, prostate, and breast cancer in observational data [11]. The American Cancer Society notes this association without establishing causality [11]. Clinicians prescribing or considering GH use off-label should review IGF-1 levels and obtain appropriate cancer screening.

The Legal and Regulatory Framework for TRT in the United States

Testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act [12]. Prescribing, dispensing, or possessing testosterone without a valid prescription is a federal offense. A valid prescription requires a licensed U.S. Physician, a documented diagnosis (typically hypogonadism confirmed by two morning serum testosterone levels), and dispensing through a licensed pharmacy.

Telehealth prescribing of testosterone has expanded significantly since 2020, but the DEA's Ryan Haight Act requires at least one in-person or video evaluation before a controlled substance can be prescribed via telemedicine [12]. The DEA finalized updated telemedicine rules in 2024 that preserve the option for video-only prescribing for testosterone with appropriate safeguards [12].

Importation of unapproved or foreign-sourced testosterone without FDA authorization is illegal, as Stallone's 2007 case illustrated for HGH.

Monitoring Requirements During TRT

Starting TRT without follow-up is not safe practice. The Endocrine Society 2018 guideline specifies monitoring at 3 to 6 months after initiation, then annually [2]:

• Serum testosterone: Target mid-normal range, generally 400 to 700 ng/dL total testosterone.
• Hematocrit: Testosterone stimulates erythropoiesis; hematocrit above 54% requires dose reduction or temporary cessation [2].
• PSA: Baseline and monitoring every 12 months; a rise of more than 1.4 ng/mL over 12 months warrants urology referral [2].
• Bone density (DXA): At baseline in men with osteopenia or osteoporosis; repeat at 1 to 2 years [2].
• Lipids and metabolic panel: Testosterone can modestly reduce HDL; cardiovascular risk reassessment annually [7].

What a 78-Year-Old Man Can Realistically Achieve With TRT

Stallone was born July 6, 1946. As of 2025 he is 78 years old.

Sarcopenia, the age-related loss of muscle mass and strength, accelerates after age 70 at roughly 1 to 2% muscle mass loss per year without intervention [13]. Resistance training remains the most evidence-supported intervention for sarcopenia at any age [13]. TRT in the context of resistance training produces additive lean mass benefits, as shown in a 2020 Cochrane review (N=1,822 across 41 trials) that found testosterone plus exercise increased muscle strength significantly more than exercise alone [14].

The realistic expectation for a healthy 70-to-80-year-old man on TRT with confirmed hypogonadism and consistent resistance training is:

• 1 to 3 kg lean mass gain over 12 months [6]
• Modest improvement in grip strength and leg press [5]
• Improved sexual function if low testosterone was contributing to dysfunction [5]
• Reduced fat mass by 1 to 2 kg [6]

Achieving a physique that resembles a 40-year-old competitive athlete requires additional factors: elite genetics, decades of trained muscle memory, professional nutrition coaching, and, in Stallone's case, a career incentive to maintain an extreme physical standard. TRT supports these goals; it does not replace the work behind them.

The table below summarizes a clinical decision framework for evaluating TRT candidacy in men aged 55 and older, based on Endocrine Society 2018 criteria and TRAVERSE cardiovascular safety data.

| Factor | Check Before Starting TRT | |---|---| | Two morning total testosterone values | Both below 300 ng/dL | | Symptoms present | At least 3 of: low libido, fatigue, loss of lean mass, depressed mood, reduced bone density | | Baseline hematocrit | Below 50% | | Baseline PSA | Below 4.0 ng/mL; no active prostate cancer workup pending | | Cardiovascular history | Review MACE risk; note TRAVERSE atrial fibrillation signal | | Fertility intentions | TRT suppresses spermatogenesis; discuss alternatives if fertility desired | | Monitoring plan confirmed | Labs at 3 months, 6 months, then annually |

Diet, Training, and the Relative Contribution of TRT

Stallone has described his diet in multiple interviews as high-protein (roughly 1 g per pound of body weight per day) and has trained six days a week for most of his adult life. These behaviors produce measurable physiological effects independent of any hormone use.

Protein intake at or above 1.2 g/kg/day is associated with preserved lean mass in older adults in a dose-response relationship, per a 2017 meta-analysis in the American Journal of Clinical Nutrition (N=2,986 across 36 randomized trials) [15]. Resistance training three or more days per week reduces the rate of sarcopenic muscle loss by approximately 30% in men over 60 [13].

TRT on top of an already optimized training and nutrition program produces incremental gains, not significant ones. The physique Stallone displays in his 60s and 70s reflects a career's worth of consistent work, not a single pharmaceutical intervention.

Risks Men Should Know Before Starting TRT

The risks of TRT are real, well-documented, and dose-dependent. Every man considering TRT deserves a complete picture:

• Erythrocytosis: Hematocrit above 54% raises thrombosis risk [2]. TRAVERSE found venous thromboembolism in 1.2% of the testosterone group vs. 0.9% placebo [7].
• Atrial fibrillation: TRAVERSE found a 45% relative increase (3.5% vs. 2.4%) [7]. Men with pre-existing AF or risk factors need cardiology input before starting.
• Testicular atrophy and infertility: Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and spermatogenesis. This effect reverses in most men after cessation but recovery may take 6 to 18 months [2].
• Acne and skin changes: Androgenic stimulation of sebaceous glands increases acne in a subset of men, particularly those with a history of acne.
• Sleep apnea: Testosterone may worsen obstructive sleep apnea; screen with an Epworth Sleepiness Scale before starting [2].
• Prostate growth: TRT is contraindicated in men with active or suspected prostate cancer. In men with treated prostate cancer, prescribing decisions require oncology input [2].